Zydus Lifesciences announced that it had received approval from the Drug Controller General of India (DCGI) for Oxemia, an oral treatment for anaemia linked with chronic kidney disease (CKD). The clinical development programme of Oxemia was one of the most significant trials for Anemia in CKD patients conducted in over 1,200 subjects, it added.

“Our life-changing findings can help patients have a better life, and we empower them with therapies so they can live healthier and more fulfilled lives. There was a possibility for an oral, safer option to currently available injectable erythropoietin-stimulating agents (ESAs). This will offer comfort to the patient and will also decrease the disease load by providing treatment at an affordable cost and enhancing the quality of life for patients suffering from CKD,” Patel added.